Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients.
COVID-19 vaccination
Hybrid immunity
Long COVID-19
Natural immunity
Post–COVID-19
SARS-CoV-2 antibodies
SARS-CoV-2 serology
SARS-CoV-2 vaccination
Unvaccinated
Vaccinated
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
31
12
2021
revised:
09
03
2022
accepted:
12
03
2022
pubmed:
28
3
2022
medline:
27
7
2022
entrez:
27
3
2022
Statut:
ppublish
Résumé
This study aimed to describe the impact of vaccination and the role of humoral responses on post-COVID-19 syndrome 1 year after the onset of SARS coronavirus type 2 (CoV-2). This prospective study was conducted through interviews to investigate post-COVID-19 syndrome 6 and 12 months after disease onset in all adult in- and outpatients with COVID-19 at Udine Hospital (March-May 2020). Vaccination status and two different serological assays to distinguish between response to vaccination (receptor-binding domain (RBD) SARS-CoV-2 IgG) and/or natural infection (non-RBD-SARS-CoV-2 IgG) were also assessed. A total of 479 patients (52.6% female; mean age: 53 years) were interviewed 13.5 months (standard deviation: 0.6 months) after acute infection. Post-COVID-19 syndrome was observed in 47.2% of patients (n = 226) after 1 year. There were no significant differences in the worsening of post-COVID-19 symptoms (22.7% vs. 15.8%; p = 0.209) among vaccinated (n = 132) and unvaccinated (n = 347) patients. The presence of non-RBD SARS-CoV-2 IgG induced by natural infection showed a significant association with post-COVID-19 syndrome (OR: 1.35; 95% CI, 1.11-1.64; p = 0.003), and median non-RBD SARS-CoV-2 IgG titres were significantly higher in long haulers than in patients without symptoms (22 kAU/L (interquartile range, 9.7-37.2 kAU/L) vs. 14.1 kAU/L (interquartile range, 5.4-31.3 kAU/L); p = 0.009) after 1 year. In contrast, the presence of RBD SARS-CoV-2 IgG was not associated with the occurrence of post-COVID-19 syndrome (>2500 U/mL vs. 0.9-2500 U/mL; OR: 1.36; 95% CI, 0.62-3.00; p = 0.441), and RBD SARS-CoV-2 IgG titres were similar in long haulers as in patients without symptoms (50% values > 2500 U/mL vs. 55.6% values > 2500 U/mL; p = 0.451). The SARS-CoV-2 vaccination is not associated with the emergence of post-COVID-19 symptoms more than 1 year after acute infection. The persistence of high serological titre response induced by natural infection, but not vaccination, may play a role in long-haul COVID-19.
Identifiants
pubmed: 35339673
pii: S1198-743X(22)00155-0
doi: 10.1016/j.cmi.2022.03.016
pmc: PMC8940723
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1140-1148Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Références
Lancet Infect Dis. 2022 Jan;22(1):43-55
pubmed: 34480857
JAMA Netw Open. 2021 May 3;4(5):e2111417
pubmed: 34037731
Sci Rep. 2021 May 26;11(1):11085
pubmed: 34040094
Crit Care Med. 2021 Sep 1;49(9):1427-1438
pubmed: 33769771
Lancet Respir Med. 2021 Dec;9(12):1467-1478
pubmed: 34416191
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
JAMA Intern Med. 2022 Jan 1;182(1):19-25
pubmed: 34747982
Clin Microbiol Infect. 2021 Oct;27(10):1507-1513
pubmed: 34111579
Clin Infect Dis. 2022 Aug 24;75(1):e1072-e1081
pubmed: 34609506
J Clin Microbiol. 2021 Oct 19;59(11):e0113821
pubmed: 34379530
Vaccines (Basel). 2022 Apr 21;10(5):
pubmed: 35632408
Mayo Clin Proc. 2022 Mar;97(3):579-599
pubmed: 35246288
MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1081-1083
pubmed: 34383732
Lancet. 2020 Sep 5;396(10252):e23
pubmed: 32866429
JCI Insight. 2022 May 23;7(10):
pubmed: 35389890
Clin Infect Dis. 2022 Jun 10;74(11):1953-1965
pubmed: 34390330
Clin Infect Dis. 2016 Aug 15;63 Suppl 2:S52-6
pubmed: 27481954
Vaccines (Basel). 2021 Feb 18;9(2):
pubmed: 33670661
Nature. 2021 Nov;599(7886):546-548
pubmed: 34815580
MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1539-1544
pubmed: 34735425
Lancet Respir Med. 2021 Jul;9(7):747-754
pubmed: 33964245
J Infect Dis. 2021 May 28;223(10):1671-1676
pubmed: 33675366
Biomedicines. 2021 Sep 28;9(10):
pubmed: 34680460
Brain Behav Immun. 2022 Jul;103:154-162
pubmed: 35447302
J Clin Immunol. 2021 Oct;41(7):1490-1501
pubmed: 34273064
Eur Respir J. 2022 Feb 3;59(2):
pubmed: 34531277